2018 Systemic Mastocytosis Drug Development- Pipeline Analysis Report
systemic mast cell disease (SMCD) is a gastrointestinal complication, where gene mutation causes excessive mast cell accumulation in liver, spleen, bone marrow. Symptoms include diarrhea, abdominal pain, rashes, breath shortness and fainting.
Around 15 companies and universities are focusing on developing treatment options for Systemic Mastocytosis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Systemic Mastocytosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Systemic Mastocytosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Systemic Mastocytosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 15 companies and universities are focusing on developing treatment options for Systemic Mastocytosis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Systemic Mastocytosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Systemic Mastocytosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Systemic Mastocytosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 SYSTEMIC MASTOCYTOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Systemic Mastocytosis Pipeline Snapshot
2.3 Systemic Mastocytosis Pipeline by Phase
2.4 Systemic Mastocytosis Pipeline by Company
2.5 Systemic Mastocytosis Pipeline by Mechanism of Action
3 SYSTEMIC MASTOCYTOSIS- COMPANY WISE PIPELINE ANALYSIS
AB Science
Allakos Inc
Arog Pharmaceuticals
Blueprint Medicines Corp
Deciphera Pharmaceuticals
Patara Pharma
Seattle Genetics Inc
Stemline Therapeutics Inc
4 SYSTEMIC MASTOCYTOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN SYSTEMIC MASTOCYTOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 SYSTEMIC MASTOCYTOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Systemic Mastocytosis Pipeline Snapshot
2.3 Systemic Mastocytosis Pipeline by Phase
2.4 Systemic Mastocytosis Pipeline by Company
2.5 Systemic Mastocytosis Pipeline by Mechanism of Action
3 SYSTEMIC MASTOCYTOSIS- COMPANY WISE PIPELINE ANALYSIS
AB Science
Allakos Inc
Arog Pharmaceuticals
Blueprint Medicines Corp
Deciphera Pharmaceuticals
Patara Pharma
Seattle Genetics Inc
Stemline Therapeutics Inc
4 SYSTEMIC MASTOCYTOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN SYSTEMIC MASTOCYTOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Systemic Mastocytosis Pipeline by Phase, H1- 2018
Figure 2: Systemic Mastocytosis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Systemic Mastocytosis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Systemic Mastocytosis Pipeline by Phase, H1- 2018
Figure 2: Systemic Mastocytosis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Systemic Mastocytosis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Systemic Mastocytosis Pipeline by Phase, H1- 2018
Table 2: Systemic Mastocytosis Pipeline by Companies, H1- 2018
Table 3: Systemic Mastocytosis Pipeline by Mechanism of Action, H1- 2018
Table 4: AB Science Systemic Mastocytosis pipeline, May 2018
Table 5: Allakos Inc Systemic Mastocytosis pipeline, May 2018
Table 6: Arog Pharmaceuticals Systemic Mastocytosis pipeline, May 2018
Table 7: Blueprint Medicines Corp Systemic Mastocytosis pipeline, May 2018
Table 8: Deciphera Pharmaceuticals Systemic Mastocytosis pipeline, May 2018
Table 9: Patara Pharma Systemic Mastocytosis pipeline, May 2018
Table 10: Seattle Genetics Inc Systemic Mastocytosis pipeline, May 2018
Table 11: Stemline Therapeutics Inc Systemic Mastocytosis pipeline, May 2018
Table 1: Systemic Mastocytosis Pipeline by Phase, H1- 2018
Table 2: Systemic Mastocytosis Pipeline by Companies, H1- 2018
Table 3: Systemic Mastocytosis Pipeline by Mechanism of Action, H1- 2018
Table 4: AB Science Systemic Mastocytosis pipeline, May 2018
Table 5: Allakos Inc Systemic Mastocytosis pipeline, May 2018
Table 6: Arog Pharmaceuticals Systemic Mastocytosis pipeline, May 2018
Table 7: Blueprint Medicines Corp Systemic Mastocytosis pipeline, May 2018
Table 8: Deciphera Pharmaceuticals Systemic Mastocytosis pipeline, May 2018
Table 9: Patara Pharma Systemic Mastocytosis pipeline, May 2018
Table 10: Seattle Genetics Inc Systemic Mastocytosis pipeline, May 2018
Table 11: Stemline Therapeutics Inc Systemic Mastocytosis pipeline, May 2018
